Aberrantly high TPO levels as observed in patients developing rebound thrombocytosis after e.g., induction chemotherapy or in other diseases, or in MDS patients treated with TPO agonists may result in significantly increased cycling of EVI1+ HSC70,71. This evidence concerns the gene MECOM and myelodysplastic syndrome.